Results 1 to 10 of about 104,266 (306)

Risk factors for irinotecan-induced hepatotoxicity: a retrospective cohort study [PDF]

open access: yesFrontiers in Oncology
BackgroundIrinotecan is a potent chemotherapeutic agent used as a neoadjuvant in colorectal cancer liver metastasis and significantly enhances five-year survival rates. Recently, irinotecan-associated hepatotoxicity was a significant concern.
Fatemah A. Alherz   +8 more
doaj   +2 more sources

Hepatotoxicity in hematologic malignancy and hematopoietic stem cell transplant patients receiving posaconazole or isavuconazole prophylaxis: a single-center cohort study [PDF]

open access: yesAntimicrobial Stewardship & Healthcare Epidemiology
Objective: To assess and compare the incidence, timing, and severity of hepatotoxicity associated with prophylactic isavuconazole and posaconazole in patients with hematologic malignancies or a history of hematopoietic stem cell transplant (HSCT ...
Samantha Steele   +3 more
doaj   +2 more sources

Association of Cytochrome P450 2E1 and N-Acetyltransferase 2 Genotypes with Serum Isoniazid Level and Anti-Tuberculosis Drug-Induced Hepatotoxicity: A Cross-Sectional Study [PDF]

open access: yesIranian Journal of Medical Sciences, 2023
Background: Anti-tuberculosis drug-induced hepatotoxicity can result from genetic polymorphism of the isoniazid (INH) metabolizing enzyme. This study aimed to determine the effect of genetic polymorphism of N-acetyltransferase 2 (NAT2) and cytochrome ...
Nasir Pourmohamadi   +4 more
doaj   +1 more source

Machine Learning Approaches to Predict Hepatotoxicity Risk in Patients Receiving Nilotinib

open access: yesMolecules, 2021
Background: Although nilotinib hepatotoxicity can cause severe clinical conditions and may alter treatment plans, risk factors affecting nilotinib-induced hepatotoxicity have not been investigated.
Jung-Sun Kim   +4 more
doaj   +1 more source

The molecular pathogenesis of triptolide-induced hepatotoxicity

open access: yesFrontiers in Pharmacology, 2022
Triptolide (TP) is the major pharmacologically active ingredient and toxic component of Tripterygium wilfordii Hook. f. However, its clinical potential is limited by a narrow therapeutic window and multiple organ toxicity, especially hepatotoxicity ...
Yeqing Hu   +19 more
doaj   +1 more source

United States Pharmacopeia (USP) comprehensive review of the hepatotoxicity of green tea extracts

open access: yesToxicology Reports, 2020
As part of the United States Pharmacopeia’s ongoing review of dietary supplement safety data, a new comprehensive systematic review on green tea extracts (GTE) has been completed.
Hellen A. Oketch-Rabah   +25 more
doaj   +1 more source

Hepatotoxicity during Treatment for Tuberculosis in People Living with HIV/AIDS. [PDF]

open access: yesPLoS ONE, 2016
Hepatotoxicity is frequently reported as an adverse reaction during the treatment of tuberculosis. The aim of this study was to determine the incidence of hepatotoxicity and to identify predictive factors for developing hepatotoxicity after people living
Carolline Araújo-Mariz   +8 more
doaj   +1 more source

Navigating liver cancer with mouse models: a comprehensive overview of HCC experimental systems [PDF]

open access: yesJournal of Liver Cancer
Hepatocellular carcinoma (HCC) is the most prevalent primary hepatic malignancy and is globally the third leading cause of cancerrelated deaths. Despite significant advancements in diagnostic techniques and therapeutic interventions, HCC prognosis ...
Ga-Young Kim   +4 more
doaj   +1 more source

Assessment of Risk Factors of Hepatotoxicity among Tuberculosis Patients

open access: yesPharmacology and Clinical Pharmacy Research, 2018
Tuberculosis is a devastating disease caused by Mycobacterium tuberculosis. If left untreated or not properly treated, it could lead to progressive tissue damage and even death. Short-term chemotherapy containing isoniazid, rifampicin.
Muhammad F. Wardhana   +2 more
doaj   +1 more source

Successful Treatment with Lorlatinib after the Development of Alectinib-Induced Liver Damage in ALK-Positive Non-Small-Cell Lung Cancer: A Case Report

open access: yesCase Reports in Oncology, 2021
Alectinib is a key drug for treating anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC). Alectinib-induced hepatotoxicity is less common than that through other ALK inhibitors, such as crizotinib or ceritinib.
Go Makimoto   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy